Eli Lilly Shares Jump 4.5% on Strong Retatrutide Phase 3 Data
LLY•Eli Lilly shares rose 4.5% after detailed Phase 3 retatrutide data showed its 4 mg dose delivered weight loss within 4% of tirzepatide’s top dose and outperformed semaglutide STEP 1 results. The company also outlined eloralintide’s Phase 3 rollout and tirzepatide’s continued market share gains.
1. Stock Reaction and Data Release
Eli Lilly shares gained 4.5% after unveiling comprehensive Phase 3 results for its obesity drug retatrutide, reinforcing confidence in the company’s cardiometabolic expansion strategy.
2. Phase 3 Trial Highlights
Lilly disclosed full findings from TRANSCEND-T2D-1 in Type 2 diabetes patients and TRIUMPH-1 in overweight or obese individuals without diabetes. The 4 mg retatrutide dose delivered weight loss within 4% of tirzepatide’s highest 15 mg dose and outperformed semaglutide STEP 1 outcomes at a lower dose, with no new safety concerns.
3. Pipeline and Commercial Updates
Lilly outlined plans for eloralintide’s Phase 3 launch, potentially one of its largest development programs. Tirzepatide continued capturing share from Novo Nordisk’s Ozempic and Wegovy in both US and international markets, supporting the company’s revenue growth trajectory.
